The Japan Cancer Research Center Central Hospital, for example, has actually achieved a short post-operative hospital stay of 4 days after surgery and a very low rate of post-operative complications. In addition, only 13 out of 6,856 deaths (0.2%) within 30 days after surgery from 2007 to 2017 maintained an extremely high level of safety globally.)
Let's take a look at Japan's treatment options in the treatment of lung cancer:
One: Segmentation of small-cell lung cancer
The standard surgical procedure for lung cancer is a lobectomy, but for small-cell lung cancer has increased in the last few years has become segmental resection, which is a reduction in the extent of resection than a lobectomy is performed.
Since 2009, experience has been gained in large national segmental resections through participation in national clinical trials to validate the effectiveness of this segmental resection. Segmental resection would require a more precise surgical procedure compared to lobectomy, but now that lobectomy is performed in a very short working time, we should be able to achieve curability and lung function preservation while performing segmental resection.
In regional resection, rapid intraoperative pathologic diagnosis to assess the degree of intraoperative malignancy and tumor lesions is an important point. This is due to the need to change the procedure from lobectomy to lobectomy.